Analyst Scoreboard: 4 Ratings For Certara
Portfolio Pulse from Benzinga Insights
Certara (NASDAQ:CERT) received mixed analyst ratings with 4 indifferent ratings in the past three months. The average 12-month price target is $17.38, up from $15.00, indicating a 15.87% increase. Analysts from Jefferies, Leerink Partners, Barclays, and UBS have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Certara, a company specializing in biosimulation software for drug discovery and development, shows a revenue growth of 1.03% as of September 30, 2023, but has a net margin of -57.22% and an ROE of -4.56%.
March 01, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Certara received indifferent ratings from analysts, with an updated average 12-month price target of $17.38, indicating optimism about its future stock price.
The increase in the average price target to $17.38 from $15.00 suggests analysts see potential for stock price growth, despite the current indifferent ratings. The adjustments in price targets by analysts from Jefferies, Leerink Partners, Barclays, and UBS reflect a response to recent developments and market conditions, which could influence investor sentiment and drive short-term stock price movements.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100